Bressler NM, Odia I, Maguire M, et al. - In a post hoc analysis carried out of DRCR Retina Network Protocol T of 652 individuals in a randomized clinical trial, researchers ascertained relationships between variations in visual acuity (VA) and in optical coherence tomography (OCT) central subfield thickness (CST) across three anti-vascular endothelial growth factor (anti-VEGF) agents (aflibercept, bevacizumab, or ranibizumab) used in a randomized clinical trial for diabetic macular edema. Advances in CST seemed to account for only a modest proportion of the total change in variances in VA. These findings did not recommend using variations in OCT CST as a substitute for variances in VA in phase 3 clinical trials assessing anti-VEGF for diabetic macular edema or as a model to notify the physician or patient about variations in VA following anti-VEGF treatment.